Long-term Efficacy and Safety of Atorvastatin in Dyslipidemic Patients Undergoing Continuous Ambulatory Peritoneal Dialysis
| Autor: | Eva Patrikalou, Athanasios Sioulis, Elias V. Balaskas, Achilleas Tourkantonis, Haralampos Kampouris |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
medicine.medical_specialty
chronic renal disease Statin medicine.drug_class hypertriglyceridemia Atorvastatin Internal medicine Hyperlipidemia medicine LDL-cholesterol In patient hypercholesterolemia business.industry dyslipidemia Hypertriglyceridemia Continuous ambulatory peritoneal dialysis Mean age atorvastatin CAPD medicine.disease HDL-cholesterol Surgery Nephrology business Dyslipidemia medicine.drug |
| Zdroj: | Hong Kong Journal of Nephrology. 5:78-83 |
| ISSN: | 1561-5413 |
| DOI: | 10.1016/s1561-5413(09)60112-5 |
| Popis: | ObjectiveLipid abnormalities are common in patients on continuous ambulatory peritoneal dialysis (CAPD) and they are risk factors for atherosclerosis. In this prospective uncontrolled study, the aim was to evaluate the efficacy and safety of atorvastatin, a new statin, in hypercholesterolemic CAPD patients with or without hypertriglyceridemia who failed to respond to diet control.MethodsFollowing a hypolipidemic diet for 2 months, atorvastatin was administered at a dose of 10 mg/day once daily in 24 patients (14 males, 10 females). Mean age was 59.9 years (range, 19-74 years) and average time on CAPD was 16.6 months (range, 4-52 months). The results were evaluated at 0, 1, 3, 6, 12, 18, 24, 30, 36, 42, and 48 months. A total of three patients received atorvastatin for longer than 48 months, eight patients received it for longer than 42 months, 10 patients for longer than 36 months, 17 patients for longer than 24 months, 20 patients for longer than 18 months, and all (24) patients for longer than 12 months.ResultsHighly significant decreases were noted in total cholesterol (from 282 ± 28 to 178 ± 22 mg/dL, 20-50%, mean, 34%; p < 0.001), low-density lipoprotein cholesterol (from 198 ± 25 to 112 ± 20 mg/dL, 21-53%, mean, 37%; p < 0.001), and triglycerides (from 256 ± 116 to 177 ± 40 mg/dL, 12-45%, mean, 28%, p < 0.01) from the sixth month. High-density lipoprotein cholesterol was significantly increased from the sixth month (from 40 ± 9 to 48 ± 9 mg/dL, 11-28%, mean, 19.4%; p < 0.01). These changes remained steady during the study. No liver function abnormalities were observed and serum creatinine kinase levels remained within normal limits during treatment. No complications or other side effects were detected.ConclusionsOur data indicate that atorvastatin, even at a low dose of 10 mg/day, is an effective, safe, and well-tolerated drug for the long-term treatment of hyperlipidemia in CAPD patients. [Hong Kong J Nephrol 2003;5(2):78-83] |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|